Research Article
Impact of Interstitial Pneumonia on the Survival and Risk Factors Analysis of Patients with Hematological Malignancy
Table 1
Demographics of HM patients with and without IP.
| | Patients | IP group | Non-IP group | | IIP | nIIP | Total |
| | Sex (male/female) | 23/12 | 499/256 | 41/20 | 499/256 | | Mean age (years; range) | 46.9 (7–87) | 52.1 (2–93) | 50.3 (7–87) | 52.1 (2–93) | | Median follow-up period (months) | 8.7 | 26.7 | 8.7 | 26.7 | | Underlying hematological disease | | | | | | Non-Hodgkin’s lymphoma | 17 | 278 (36.8%) | 26 (42.6%) | 278 (36.8%) | | B-cell NHL | 10 | 223 | 19 | 223 | | T-cell NHL | 7 | 55 | 7 | 55 | | Hodgkin’s lymphoma | 1 | 25 (3.3%) | 5 (8.2%) | 25 (3.3%) | | Acute lymphoblastic leukemia | 8 | 80 (10.6%) | 10 (16.4%) | 80 (10.6%) | | Pre-B ALL | 5 | 59 | 6 | 59 | | T-cell ALL | 2 | 17 | 3 | 17 | | B-cell ALL | 1 | 4 | 1 | 4 | | Acute myeloid leukaemia | 5 | 162 (21.5%) | 8 (13.1%) | 162 (21.5%) | | Chronic myeloid leukaemia | 3 | 80 (10.6%) | 7 (11.5%) | 80 (10.6%) | | Chronic phase | 0 | — | 0 | — | | Accelerated phase | 1 | — | 5 | — | | Blast crisis | 2 | — | 2 | — | | Chronic lymphoblastic leukaemia | 0 | 26 (3.4%) | 0 | 26 (3.4%) | | Multiple myeloma | 1 | 104 (13.8%) | 5 (8.2%) | 104 (13.8%) | | Total | 35 (57%) | 755 | 61 | 755 |
|
|
HM: hematological malignancy; IP: interstitial pneumonia; IIP: infectious interstitial pneumonia; nIIP: noninfectious interstitial pneumonia; non-IP group: the hematological malignancy patients without interstitial pneumonia; NHL: non-Hodgkin’s lymphoma; ALL: acute lymphoblastic leukaemia.
|
